Evidence map›Paper›PMID 30174451›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2018

Association between polymorphisms in

Chun-Yang Wang, Shu Liu, Xiao-Nv Xie, Zhi-Ying Luo, Li Yang, Zhi-Rong Tan

Open access · goldAbstract read
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Chun-Yang WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China, tanzr@163.com; 15111495590@163.com.
Shu LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China, tanzr@163.com; 15111495590@163.com.
Xiao-Nv XieDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China, tanzr@163.com; 15111495590@163.com.
Zhi-Ying LuoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China, tanzr@163.com; 15111495590@163.com.
Li YangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China, tanzr@163.com; 15111495590@163.com.
Zhi-Rong TanDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China, tanzr@163.com; 15111495590@163.com.
Central South University · CNPharmacoGenetics (China) · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe small peptide transporter 1 (PepT-1) and adipose phospholipase A2 (AdPLA) play a key role in the development of obesity. However, there are no data assessing the impact of PepT-1 ( MATERIALS AND

methodsA total of 611 participants were enrolled in the study, and 9 SNPs in the

resultsThe genotype frequencies (

conclusionData indicate that the selected 9 SNPs in

Indexed as

BMIChinese subjectsgenotypingobesitySNPs

Identifiers

PMID30174451
PMCPMC6110659
OpenAlexW2888640327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.